Table 3.

Characteristics of endometrial cancer cases and controls

CharacteristicCases* (n = 371), n (%)Controls* (n = 420), n (%)
Age (y)
    50-5494 (25)130 (31)
    55-59103 (28)103 (25)
    60-6497 (26)101 (24)
    65-6977 (21)86 (20)
Education (y)
    ≤1235 (9)29 (7)
    13-16219 (59)217 (52)
    ≥17117 (32)174 (41)
No. births
    065 (18)43 (10)
    146 (12)35 (8)
    ≥2260 (70)342 (81)
Oral contraceptive use (y)
    Never143 (39)127 (31)
    <5150 (41)157 (39)
    ≥576 (21)122 (30)
Cigarette smoking
    Never201 (54)178 (42)
    Former (>1 y ago)132 (36)169 (40)
    Current (in the past year)38 (10)73 (17)
Body mass index (kg/m2)
    <21.9762 (17)104 (25)
    21.97-24.2147 (13)104 (25)
    24.22-28.29101 (27)107 (25)
    ≥28.29160 (43)105 (25)
Postmenopausal hormone regimen use§
    Never153 (42)182 (44)
    Only unopposed estrogen37 (10)13 (3)
    Only estrogen + progestin121 (33)176 (42)
    Unopposed estrogen and estrogen + progestin46 (13)41 (10)
    Unopposed progestin and estrogen + progestin4 (1)1 (<1)
    Only unopposed progestin6 (2)3 (1)
  • * Distributions of characteristics are reported for non-Hispanic Caucasian women only, because there were too few African American and/or Hispanic women (11 cases and 26 controls) to either stratify on or control for race/ethnicity. Therefore, they were excluded from analyses.

  • Two cases and 14 controls either used sequential oral contraceptives or used unknown oral contraceptives during that time when sequential oral contraceptives were marketed; these data are not included above.

  • Data were missing for body mass index for one case.

  • § Postmenopausal use of estrogen and progestin hormonal pills or patches for ≥6 months. Data were missing for four cases and four controls.